Impax Refiles NDA After Manufacturing Woes

Drug Industry Daily
A A
Impax said Friday it has refiled an NDA for its Parkinson’s disease drug Rytary after implementing quality systems improvements at the plant where the drug was slated to be made.

To View This Article:

Login

Subscribe To Drug Industry Daily